Treat Stroke to Target

NACompletedINTERVENTIONAL
Enrollment

2,873

Participants

Timeline

Start Date

March 15, 2010

Primary Completion Date

May 26, 2019

Study Completion Date

May 26, 2019

Conditions
Ischemic StrokeTransient Ischemic AttackAtherosclerotic Stenosis
Interventions
PROCEDURE

Target : 100 mg/dL (+/-10 mg/dL)

Statin +/- other lipid lowering therapy during 3 years, Target : LDL-C =100 mg/dL (+/-10 mg/dL), recording recurrent non fatal stroke, non fatal MI, and vascular death and others endpoints such as new onset diabetes, hemorrhagic strokes.

PROCEDURE

70 mg/dL

Statin +/-lipid lowering therapy during eight and a half years maximum, Target : LDL-C concentration of less than 70 mg/dL, recording recurrent of non fatal stroke, non fatal IM, and vascular death and others endpoints such as: new onset diabetes, hemorrhagic strokes.

Trial Locations (2)

75018

BICHAT HOSPITAL Departement of Neurology, Paris

BICHAT HOSPITAL Department of neurology and stroke center, Paris

Sponsors

Collaborators (2)

All Listed Sponsors
collaborator

Pfizer

INDUSTRY

collaborator

AstraZeneca

INDUSTRY

collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Assistance Publique - Hôpitaux de Paris

OTHER